임상시험 트래커

추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov

14건 표시

2상모집 중· Varicella
Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination
리드: GC녹십자
상세 →NCT05422508
2상완료· Anthrax
A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109
리드: GC녹십자
상세 →NCT01624532
2상완료· Chronic Liver Disease
Part A: In Patients With Chronic Liver Diseases, LAENNEC (Human Placenta Hydrolysate) is to Assess Safety and Tolerability After the Doses of Doses. Part B: Part A, it is to Determine the Optimal Dose by Evaluating Two Capacity and Placebo Groups.
리드: GC녹십자
상세 →NCT05532124
2상상태 미확인· Urachal Cancer
A Multicenter Prospective Phase II Study of Modified FOLFIRINOX for 1st Line Treatment for Advanced Urachus Cancer
협력: GC녹십자
상세 →NCT04611724
2상완료· Covid19
COVIDIG (COVID-19 Hyper-ImmunoGlobulin)
리드: GC녹십자
상세 →NCT04555148
2상완료· Autoimmune Encephalitis
Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis:
리드: GC녹십자
상세 →NCT04175522
2상상태 미확인· Tetanus
A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3111 in Healthy Adults
리드: GC녹십자
상세 →NCT04238975
2상상태 미확인· Hepatitis B
A Study of GC1102(Recombinant Hepatitis B Immunoglobulin) in Chronic Hepatitis B Patients
리드: GC녹십자
상세 →NCT03801798
2상완료· Influenza, Human
A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Elderly Healthy Subjects
리드: GC녹십자
상세 →NCT03657719
2상상태 미확인· Mucopolysaccharidosis II
Study of Idursulfase-beta (GC1111) in Hunter Syndrome
리드: GC녹십자
상세 →NCT02663024
2상상태 미확인· Chemotherapy Induced Neutropenia
Pegteograstim in Children With Solid Tumors
협력: GC녹십자
상세 →NCT02787876
2상완료· Hepatitis B Infection
A Phase 2 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in HBV-related Liver Transplant Recipients
리드: GC녹십자
상세 →NCT02304315
2상상태 미확인· Gastritis
Phase II Study to Evaluate the Efficacy and Safety of GC6101A in Subjects With Gastritis
리드: GC녹십자
상세 →NCT02353039
2상조기 종료· Cerebral Infarction
The Efficacy and Safety Study of ALbumin Therapy in Acute Ischemic Stroke
협력: GC녹십자
상세 →NCT01684462

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.